Break out session on Neurodegeneration 2024
Welcome to this years Neurodegeneration session chaired by:
Dr. Daniel Ferreira, Karolinska Institutet
Dr. Amit Kumar, Karolinska Institutet
Dr. Baayla Boon, Mayo Clinic
Dr. Christopher Schwarz, Mayo Clinic
Venue 16 October: Kerstin Hagenfeldt ( J3:14) Bioclinicum, Karolinska Hospital,
Venue 17 October; Scheelesalen Tomtebodavägen 6,
Involvement of intracellular adhesion molecule 1 (ICAM1) in the secondary insults associated with reactive astrogliosis in Parkinson’s disease
Dr. Avishek Roy, PhD, Karolinska Institutet
Structural brain MRI markers associated with odor identification decline
Dr. Javier Oltra, PhD, Karolinska Institutet
Repopulation with tolerogenic MHC-mismatched microglia-like cells as a therapeutic approach in MS
Dr. Irene Benito Cuesta, PhD, Karolinska Institutet
Break
Neuropathology after treatment with aducanumab and amyloid related imaging abnormalities
Dr. Baayla Boon, MD, PhD, Mayo Clinic
Assessment of innate and adaptive immune response in a novel humanized mouse model of Alzheimer’s disease
Dr. Ruchi Gera, PhD, Karolinska Institutet
Amyloid Beta influences plasmin activity in-vitro – relevance for Alzheimer's Disease
Dr. Aditya Kumar Kar, PhD, Karolinska Institutet
Break
Characterization of a limbic-predominant amnestic neurodegenerative syndrome
Dr. Nick Corriveau-Lecavalier, PhD, Mayo Clinic
Alpha-synuclein RT-QuIC for Dementia with Lewy bodies
Dr. Rakesh Kumar, PhD, Karolinska Institutet
Markers of cerebrovascular disease in Dementia with Lewy bodies
Ms. Anna Rennie, Karolinska Institutet
End of session
Transitions and critical points in young-onset dementia
Dr. Malin Aspö, Karolinska Institutet, Karolinska University Hospital
Patients with dementia with Lewy bodies display alterations in their cognitive connectome from prodromal stages
Ms. Roraima Yanez-Perez, Karolinska Institutet, University of La Laguna
Blood biomarkers of Alzheimer’s disease and transitions from normal cognition to cognitive impairment and dementia: a population-based study
Dr. Martina Valletta, MD, Karolinska Institutet
Break
A Comparative Analysis of Polygenic Risk Scores for Predicting ADRD in UK Biobank
Dr. Shayan Mostafaei, PhD, Karolinska Institutet
Hippocampal cholinergic activity is altered in an APP-knock-in (AppNL-G-F) AD mice model
Dr. Sumonto Mitra, PhD, Karolinska Institutet
A multiple-drug therapy benefits cognition and reduces amyloid plaques in APP NL-G-F knock-in mice, in a sex-specific manner.
Francesca Eroli, Karolinska Institutet
Break
Comparing de-facing software MiDeFace and mri_reface according to privacy protection and effects on downstream measurements
Dr. Christopher Schwarz, PhD, Mayo Clinic
In Vivo and Post-Mortem Validation of Imaging-based Cholinergic Biomarkers in Alzheimer's and Dementia with Lewy Body
Dr. Milan Nemy, PhD, Karolinska Institutet
Neuronal alterations during the onset of Alzheimer’s disease in the human brain cortex
Dr. Luis Enrique Arroyo Garcia, PhD, Karolinska Institutet